Drugs / Rhenium Re 188 P2045
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02030184 | Jun 2017 → Jun 2019 | large cell neuroendocrine carcinoma, small cell lung carcinoma | University of Maryland, Baltimore | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00100256 | Jan 2004 → Jun 2009 | non-small cell lung carcinoma, small cell lung carcinoma | Andarix Pharmaceuticals | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-09-22 | Andarix Pharmaceuticals | Results Andarix Pharmaceuticals’ Targeted Therapy Reduced Tumor Size in Lung Cancer Study andarix.com ↗
The patients who received R188 P2045 at the therapeutic dose had a 25% reduction in tumor mass based on image analysis versus typical results of stable disease from standard of care. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-09-22 | Andarix Pharmaceuticals | Andarix Pharmaceuticals’ Targeted Therapy Reduced Tumor Size in Lung Cancer Study andarix.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rhenium Re 188-P2045 | “Rhenium Re 188 P2045” NCT00100256 ↗ |
| Known as | BAY86-5284 | “Rhenium (Re 188 P2045, BAY86-5284)” NCT00100256 ↗ |